SLC7A5 and non-small cell lung carcinoma: Besides that, the roles of LDLRAD3 as a therapeutic target for NSCLC needed to be continuously investigated in vivo and a special mTORC1 inhibitor was required to be selected to confirm the activation of this pathway by the LDLRAD3-miR-20a-5p-SLC7A5 axis.